Oncostatin M in the development of metabolic syndrome and its potential as a novel therapeutic target

Area of Science:

• Immunology
• Metabolism
• Endocrinology

Background:

• Oncostatin M (OSM), an IL-6 family cytokine, influences cell growth, development, and inflammation.
• A link between OSM and metabolic syndrome in mice has been recently identified.

Purpose of the Study:

• To investigate the role of OSM in metabolic syndrome.
• To evaluate OSM as a potential therapeutic target for metabolic disorders.

Main Methods:

• Utilized OSMRβ knockout mice to study OSM deficiency effects.
• Administered OSM treatment to mice with diet-induced metabolic disorders.
• Analyzed adipose tissue inflammation, insulin resistance, and hepatic steatosis.
• Assessed macrophage phenotype and hepatic lipid metabolism gene expression.

Main Results:

• OSMRβ knockout mice developed late-onset obesity, adipose tissue inflammation, and insulin resistance.
• High-fat diet exacerbated metabolic disorders in OSMRβ knockout mice.
• OSM treatment ameliorated obesity, adipose tissue inflammation, insulin resistance, and hepatic steatosis.
• OSM shifted adipose tissue macrophages to an anti-inflammatory M2 phenotype.
• OSM reduced hepatic fatty acid content by regulating lipid metabolism enzymes.

Conclusions:

• OSM plays a protective role against metabolic syndrome development and progression.
• OSM demonstrates therapeutic potential for treating metabolic syndrome.
• Targeting OSM may offer a novel strategy for managing metabolic disorders.